大流行期间指导非大流行重症医学研究的原则
本文由跨专业临床研究组通过文献回顾、伦理文件与专家评论分析及利益相关方咨询,提出大流行期间非大流行重症研究的原则与决策框架。核心观点为:临床研究应优先惠及COVID-19患者,但理想情况下不应过度损害非COVID-19患者利益;继续非大流行研究需考虑疫情状态、当地管辖指导、床旁及研究人员能力与安全、已入组患者处置、各研究特征、研究监管及最终报告要求。决策应基于客观透明标准,权衡暂停或继续,并随疫情消退重新评估。
要点
- 大流行期间临床研究应优先开展针对COVID-19的研究以惠及患者,但理想情况下不应过度损害非COVID-19患者。
- 继续非大流行研究需逐项审议:疫情状态、当地管辖指导、床旁及研究人员能力与安全、已入组患者处置、各研究特征、研究监管及最终报告要求。
- 决策应基于客观透明标准,考虑床旁及研究人员安全、感染控制、知情同意模式、方案复杂性、数据收集及实施完整性。
- 暂停或继续非大流行研究的决定应成比例、透明,并随疫情消退重新评估。
- 许多非专门针对COVID-19的研究仍与COVID-19患者相关。
适用人群与场景
- ICU中感染与未感染COVID-19的患者
- 临床研究涉及床旁及研究人员
研究设计与关键结果
- 通过面对面、电子邮件及视频会议交流,组建跨专业临床研究组,回顾2010年至今的实证研究、伦理文件及专家评论,并查阅2020年3月至2020年5月的传统及社交媒体帖子,利益相关方咨询包括科学、伦理、临床及行政领导。
- 继续非大流行研究的考虑因素包括:疫情状态、当地管辖指导、床旁及研究人员能力与安全、已入组非大流行研究患者的处置、各非大流行研究的特征分析、研究监管及最终报告要求。
- 继续非大流行研究的决策应使用客观透明标准,考虑床旁及研究人员安全、感染控制、知情同意模式、方案复杂性、数据收集及实施完整性。
- 暂停或继续非大流行研究的决定应成比例、透明,并随疫情消退重新评估。
证据类型、等级与局限
- 证据类型:跨专业临床研究组共识性建议(基于文献回顾、伦理文件、专家评论及利益相关方咨询)
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,大流行期间应优先开展针对COVID-19的临床研究,但不应过度损害非COVID-19患者。
- 作者认为,继续非大流行研究应基于客观透明标准逐项审议疫情状态、当地指导、人员安全与能力、已入组患者处置、研究特征、监管及报告要求。
- 作者认为,暂停或继续非大流行研究的决定应成比例、透明,并随疫情消退重新评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To describe the importance of critical care clinical research that is not pandemic-focused during pandemic times; outline principles to assist in the prioritization of nonpandemic research during pandemic times; and propose a guiding framework for decisions about whether, when and how to continue nonpandemic research while still honoring the moral and scientific imperative to launch research that is pandemic-focused.
DESIGN/DATA SOURCES: Using in-person, email, and videoconference exchanges, we convened an interprofessional clinical research group, conducted a literature review of empirical studies, ethics documents and expert commentaries (2010 to present), and viewed traditional and social media posts (March 2020 to May 2020). Stakeholder consultation involved scientific, ethics, clinical, and administrative leaders.
SETTING: Clinical research in the ICU.
PATIENTS: Patients with and without coronavirus disease 2019.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: While clinical research should be prioritized to advantage patients with coronavirus disease 2019 in order to care for affected patients, it ideally would not unduly disadvantage patients without coronavirus disease 2019. Thus, timely, rigorous, relevant, and ethical clinical research is needed to improve the care and optimize outcomes for both patients with and without coronavirus disease 2019, acknowledging how many studies that are not exclusively focused on coronavirus disease 2019 remain relevant to patients with coronavirus disease 2019. Considerations to continue nonpandemic-focused research include the status of the pandemic, local jurisdictional guidance, capacity and safety of bedside and research personnel, disposition of patients already enrolled in nonpandemic studies, analyzing characteristics of each nonpandemic-focused study, research oversight, and final reporting requirements.
CONCLUSIONS: Deliberation about continuing nonpandemic research should use objective, transparent criteria considering several aspects of the research process such as bedside and research staff safety, infection control, the informed consent model, protocol complexity, data collection, and implementation integrity. Decisions to pause or pursue nonpandemic research should be proportionate, transparent, and revisited as the pandemic abates.
参考来源
- Cook DJ, Kho ME, Duan EH, et al. Principles Guiding Nonpandemic Critical Care Research During a Pandemic. Crit Care Med. 2020. PMID: 32796181. doi:10.1097/CCM.0000000000004538
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。